Website stats for Evaluategroup - evaluategroup.com
Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual Evaluate Pharma World Preview.
evaluategroup.com was registered 2 decades 5 years ago. It has a alexa rank of #4,553,122 in the world. It is a domain having .com extension. It is estimated worth of $ 240.00 and have a daily income of around $ 1.00. As no active threats were reported recently, evaluategroup.com is SAFE to browse.
Traffic Report
| Daily Unique Visitors: | 193 |
| Daily Pageviews: | 386 |
Estimated Valuation
| Income Per Day: | $ 1.00 |
| Estimated Worth: | $ 240.00 |
Search Engine Indexes
| Google Indexed Pages: | Not Applicable |
| Yahoo Indexed Pages: | Not Applicable |
| Bing Indexed Pages: | Not Applicable |
Search Engine Backlinks
| Google Backlinks: | Not Applicable |
| Bing Backlinks: | Not Applicable |
| Alexa BackLinks: | Not Applicable |
Safety Information
| Google Safe Browsing: | No Risk Issues |
| Siteadvisor Rating: | Not Applicable |
| WOT Trustworthiness: |
 Very Poor
|
| WOT Privacy: |
Very Poor
|
| WOT Child Safety: |
Very Poor
|
Website Ranks & Scores
| Alexa Rank: | 4,553,122 |
| PageSpeed Score: | 89 ON 100 |
| Domain Authority: |
49 ON 100 
|
| Bounce Rate: | Not Applicable |
| Time On Site: | Not Applicable |
Web Server Information
Hosted IP Address:
34.255.238.89
Hosted Country:
GB
Location Latitude:
53.1905Location Longitude:
-2.89189Search Engine Results For evaluategroup.com
Evaluate's Competitors, Revenue, Number of Employees, Funding ...
Weigh In. Founded: 1996. Status: PrivateIndependent Company. SIC Code: 2836 NAICS listing ». Website: http://www.evaluategroup.com/. Est. Annual Revenue.
EvaluatePharma: Worldwide prescription drug sales accelerate to ...
Jun 6, 2018 ... For more information please visit: www.evaluategroup.com. On Twitter: @ evaluatepharma, @evaluatemedtech, @evaluateJP @epclinicaltrial, ...
Evaluate - Fast Track
Activity, Life sciences analyst. Location, Central London. Profits £000, 3,406. Sales £000, 16,743. Staff, 90. Founded, 1996. Website, www.evaluategroup.com ...
EvaluatePharma World Preview 2017, Outlook to 2022 - PDF4PRO
EP Vantage 2017 Preview - info.evaluategroup.com. info.evaluategroup.com. regions of the world which, together with hotspots of regional instability, continues ...
The work of the European Medicines Agency_Vital for EU public and ...
Retrieved from http://www.evaluategroup.com/public/reports/Evaluate- Pharmaceutical-Innovation-in-Europe.aspx#anchorwebsite. 1 European Federation of ...
ORPHAN DRUG REPORT 2014
Oct 27, 2014 ... at: www.evaluategroup.com/orphandrug2014. About EvaluatePharma. Since 1996 EvaluatePharma has been providing senior decision ...
Rare Diseases Archives - Kx Advisors
Jul 9, 2020 ... http://info.evaluategroup.com/rs/evaluatepharmaltd/images/2014OD.pdf.
in Hepatoblastoma - Gastroenterology
Evaluate. ChiRhoStim (human secretin for injection) is now available Evaluate [ updated 2012 Sep 25]. Available: http://evaluategroup.
Partners and Sponsors 2017 – Swiss HLG Winter Conference 2017 ...
www.evaluategroup.com. Labatec Pharma. www.labatecpharma.com. Medinova AG. www.medinova.ch. Neovii Biotech. www.neovii.com. Roivant Sciences.
Expertise and Infrastructure Matter | Boehringer Ingelheim
http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=24763. Accessed July 19, 2018. 14. Boehringer Ingelheim website. Press release. Boehringer ...
Pharma commercial intelligence, news & analysis | Evaluate
Trusted commercial intelligence, consensus forecasts, Vantage news and analysis for pharma, biotech and medtech industry - Explore Evaluate.
A Study on the Application and Use of Artificial Intelligence to ...
Jun 24, 2019 ... Orphan Drug Report. 2018. http://info.evaluategroup.com/rs/607-YGS-364/ images/OD2018-IG.pdf.
Article : Can Competitive Intelligence Strategies Help in Orphan ...
7. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. 8. http://info. evaluategroup.com/rs/607-YGS-364/images/EPOD17.pdf. Suggested Reading
Evaluate Ltd: Worldwide Prescription Drug Sales to Exceed Trillion ...
Jun 24, 2014 ... For more information visit: www.evaluategroup.com. On Twitter: @ evaluatepharma, @evaluatemedtech, @epclinicaltrial. Issued for and on ...
Rare diseases, large costs - Optum
Accessed at: https://info.evaluategroup.com/OD2018-SOC.html; Annals of Neurology. “Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica ...
Evaluate Group Limited - Company Profile - Endole
Evaluate Group Limited is an active company located in London, City of London. View Evaluate Group Limited profile, shareholders, contacts, financials, industry ...
Overview of the Life Sciences Landscape in the ... - Harvard Postdocs
Oct 28, 2019 ... ... Evaluate Pharma The Future of Medtech Report World. Preview 2013 Outlook to 2018 Report. www.evaluategroup.com/MedTechWP2013 ...
Evaluate Pharma Login | Accedi Evaluate Pharma
Mar 1, 2021 ... https://info.evaluategroup.com/rs/evaluatepharmaltd/images/EP240614.pd... Welcome to the EvaluatePharma® World Preview 2014, Outlook to ...
Megafunds: The Concept - Amazon AWS
- http://download2.eurordis.org.s3.amazonaws.com/ecrd/ECRD_2018/Speaker_Presentations/0103-athanasiou.pdf
(d) Evaluate Pharma Orphan Drug Report 2017 http://www.evaluategroup.com/ public/Reports/EvaluatePharma-Orphan-Drug-Report-2017.aspx. © 2018 WDO.
Angel and Venture Alert: The Case for Investing in Orphan Drugs ...
Dec 9, 2020 ... EvaluatePharma “Orphan Drug Report 2017”, http://info.evaluategroup.com/rs/ 607-YGS-364/images/EPOD17.pdf,; Ibid; Rare Disease Report ...
What's in store for 2018 in the pharma and biotech industry?
Dec 8, 2017 ... drug pricing debate in US expected to ease. Sign up for your free email newsletter. The report can be downloaded at www.evaluategroup.com/ ...
Quixin - definition of Quixin by The Free Dictionary
Santen Pharmaceutical submits new drug application for Quixin antibacterial eye drops," March 2000, June 2017, http://www.evaluategroup.com/Universal/ ...
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
| H1 Headings: | Not Applicable | H2 Headings: | 3 |
| H3 Headings: | 5 | H4 Headings: | Not Applicable |
| H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
| Total IFRAMEs: | 1 | Total Images: | 17 |
| Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
Two Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| Evaluate Vantage | 5 | 1.121 % | No |
| Evaluate Pharma | 3 | 0.673 % | No |
| 08 2021 | 3 | 0.673 % | No |
| June 08 | 3 | 0.673 % | No |
| 09 2021 | 2 | 0.448 % | No |
| datadriven daily | 2 | 0.448 % | No |
| daily news | 2 | 0.448 % | No |
| Thought Leadership | 2 | 0.448 % | No |
| FIND OUT | 2 | 0.448 % | No |
| Custom Solutions | 2 | 0.448 % | No |
| cookies on | 2 | 0.448 % | No |
| OUT MORE | 2 | 0.448 % | No |
| and analysis | 2 | 0.448 % | No |
| Drug Forecasts | 2 | 0.448 % | No |
| news and | 2 | 0.448 % | No |
| analysis on | 2 | 0.448 % | No |
| Subscriber Sign | 2 | 0.448 % | No |
| June 09 | 2 | 0.448 % | No |
| Contact Us | 2 | 0.448 % | No |
| Sign Up | 2 | 0.448 % | No |
Four Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| and analysis on pharma | 2 | 0.448 % | No |
| analysis on pharma biotech | 2 | 0.448 % | No |
| news and analysis on | 2 | 0.448 % | No |
| daily news and analysis | 2 | 0.448 % | No |
| datadriven daily news and | 2 | 0.448 % | No |
| pharma biotech and medtech | 2 | 0.448 % | No |
| on pharma biotech and | 2 | 0.448 % | No |
| Contact Us Sign Up | 2 | 0.448 % | No |
| Solutions Improve your strategic | 1 | 0.224 % | No |
| Improve your strategic decisionmaking | 1 | 0.224 % | No |
| Custom Solutions Improve your | 1 | 0.224 % | No |
| OUR SERVICES Custom Solutions | 1 | 0.224 % | No |
| SERVICES Custom Solutions Improve | 1 | 0.224 % | No |
| datadriven solutions that draw | 1 | 0.224 % | No |
| customised datadriven solutions that | 1 | 0.224 % | No |
| strategic decisionmaking with customised | 1 | 0.224 % | No |
| MORE OUR SERVICES Custom | 1 | 0.224 % | No |
| decisionmaking with customised datadriven | 1 | 0.224 % | No |
| with customised datadriven solutions | 1 | 0.224 % | No |
| your strategic decisionmaking with | 1 | 0.224 % | No |
HTTP Header Analysis
Status-Code: 200
Status: 200 OK
Server: nginx
Date: Wed, 09 Jun 2021 23:51:28 GMT
Content-Type: text/html; charset=UTF-8
Content-Length: 10680
Connection: keep-alive
Cache-Control: max-age=600, public
X-Drupal-Dynamic-Cache: MISS
Link:
X-UA-Compatible: IE=edge
Content-language: en
X-Content-Type-Options: nosniff
Expires: Sun, 19 Nov 1978 05:00:00 GMT
Last-Modified: Wed, 09 Jun 2021 23:45:45 GMT
ETag: W/"1623282345"
Content-Encoding: gzip
Vary: Cookie, Accept-Encoding
X-Cache: HIT
Accept-Ranges: bytes
Strict-Transport-Security: max-age=15768000; always;
Domain Information
| Domain Registrar: |
Network Solutions, LLC
|
|---|---|
| Registration Date: | 1999-10-08 2 decades 5 years 1 month ago |
| Last Modified: | 2020-08-08 4 years 3 months 2 weeks ago |
Domain Nameserver Information
| Host | IP Address | Country | |
|---|---|---|---|
| ns-1050.awsdns-03.org | |
205.251.196.26 |  United States |
| ns-1690.awsdns-19.co.uk | |
205.251.198.154 | United States |
| ns-448.awsdns-56.com | |
205.251.193.192 | United States |
| ns-747.awsdns-29.net | |
205.251.194.235 | United States |
DNS Record Analysis
| Host | Type | TTL | Extra |
|---|---|---|---|
| evaluategroup.com | A | 294 |
IP: 34.255.238.89 |
| evaluategroup.com | A | 294 |
IP: 52.209.127.87 |
| evaluategroup.com | NS | 86400 |
Target: ns-1690.awsdns-19.co.uk |
| evaluategroup.com | NS | 86400 |
Target: ns-448.awsdns-56.com |
| evaluategroup.com | NS | 86400 |
Target: ns-747.awsdns-29.net |
| evaluategroup.com | NS | 86400 |
Target: ns-1050.awsdns-03.org |
| evaluategroup.com | SOA | 900 |
MNAME: ns-1690.awsdns-19.co.uk RNAME: awsdns-hostmaster.amazon.com Serial: 1 Refresh: 7200 Retry: 900 Expire: 1209600 |
| evaluategroup.com | MX | 300 |
Priority: 10 Target: eu-smtp-inbound-1.mimecast.com |
| evaluategroup.com | MX | 300 |
Priority: 10 Target: eu-smtp-inbound-2.mimecast.com |
| evaluategroup.com | TXT | 300 |
TXT: v=spf1 a mx ip4:82.71.224.37 ip4:5.79.60.197 include:mktomail.com include:eu._netblocks.mimecast.com include:_spf.salesforce.com include:spf.protection.outlook.com ~all |
| evaluategroup.com | TXT | 300 |
TXT: 0ed1fe018a4e8af995d0b1420bbde309648c393f fb |
| evaluategroup.com | TXT | 300 |
TXT: MS=ms24014293 |
Full WHOIS Lookup
Registry Domain ID:
11113607_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.networksolutions.com
Registrar URL:
http://networksolutions.com
Updated Date:
2020-08-07T19:15:41Z
Creation Date:
1999-10-08T12:03:34Z
Registry Expiry Date:
2025-10-08T12:03:34Z
Registrar: Network Solutions,
LLC
Registrar IANA ID: 2
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
+1.8003337680
Domain Status: clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Name Server:
NS-1050.AWSDNS-03.ORG
Name Server:
NS-1690.AWSDNS-19.CO.UK
Name Server: NS-448.AWSDNS-56.COM
Name
Server: NS-747.AWSDNS-29.NET
DNSSEC: unsigned
URL of the ICANN
Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>>
Last update of whois database: 2021-06-09T23:51:25Z
Similarly Ranked Websites
Santos R. Guerra Faro | Analista SEO y Desarrollo Wordpress
Apasionado por el Posicionamiento Web, melómano, CatLover, defensor del Ambiente Completo y Fotógrafo Aficionado.
4,553,127 
$ 240.00
Купить автозапчасти для иномарок в интернет магазине texnacar.ru
Большой каталог автозапчастей для иномарок. Купить запчасти выгодно, со скидкой в Москве....
4,553,229 $ 240.00
Georgii — Creative Frontend Developer
Hello! My name is Georgii Khidzhakadze. I'm a Creative Frontend Developer based on interactions and slick animations
4,553,310 $ 240.00